Literature DB >> 23007134

Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis.

Anuradha Krishnan1, Xia Li, Winstonwhei-Yang Kao, Kimberly Viker, Kim Butters, Howard Masuoka, Bruce Knudsen, Gregory Gores, Michael Charlton.   

Abstract

Lumican, an extracellular matrix proteoglycan was previously shown to be upregulated with increasing severity of nonalcoholic steatohepatitis (NASH). Although lumican is involved in collagen fibrillogenesis in extra-hepatic tissues, little is known about the role of lumican in hepatic disease. We therefore determined lumican expression in etiologies other than clinical NASH. Our results indicated that lumican is upregulated in clinical samples of hepatitis C virus infection, in experimental rodent models of chronic and acute liver injury and could additionally be induced in vitro in response to the pro-fibrotic cytokine transforming growth factor β1 (TGFβ1) and to lipotoxic palmitic acid. Together, these results suggested a role for lumican in hepatic fibrosis. To investigate the functional role of lumican in hepatic fibrosis, lumican null (Null) and wild-type (WT) littermates were administered carbon tetrachloride intra-peritoneally. Serum and liver tissue were analyzed for indices of liver injury, fibrosis, matrix turnover, and proliferation. Hepatic fibrosis was greatly reduced in null animals (P<0.05). Paradoxically, gene expression of fibrosis-related genes such as TGFβ1 and collagen 1 was numerically higher in null animals though statistically insignificant from WT animals. On the other hand, α smooth muscle actin expression (α-SMA), a marker for activated fibroblasts, the main contributors of collagen production was significantly higher (P<0.05) in null animals as compared with WT littermates. Among the matrix metalloproteases (MMP), MMP13 was significantly increased (P<0.05) in null animals. Ultra-structural imaging indicated differences in the organization and spatial distribution of hepatic collagen fibrils of null and WT mice. Cell proliferation was significantly increased (P<0.05) in null animals. We conclude that lumican is a prerequisite for hepatic fibrosis. The protective effect of lumican deficiency in hepatic fibrosis appears to be downstream of collagen production and mediated through the combined effects of impaired collagen fibrillogenesis, increased matrix turnover, and an enhanced proliferative response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007134      PMCID: PMC3810270          DOI: 10.1038/labinvest.2012.121

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  55 in total

1.  Expression of lumican in thickened intima and smooth muscle cells in human coronary atherosclerosis.

Authors:  Munehiko Onda; Toshiyuki Ishiwata; Kiyoko Kawahara; Ruojiao Wang; Zenya Naito; Yuichi Sugisaki
Journal:  Exp Mol Pathol       Date:  2002-04       Impact factor: 3.362

2.  Enhanced expression of lumican inhibited the attachment and growth of human embryonic kidney 293 cells.

Authors:  Toshiyuki Ishiwata; Tetsushi Yamamoto; Kiyoko Kawahara; Yoko Kawamoto; Yoko Matsuda; Shunji Ishiwata; Zenya Naito
Journal:  Exp Mol Pathol       Date:  2010-02-04       Impact factor: 3.362

3.  Primary structure of human lumican (keratan sulfate proteoglycan) and localization of the gene (LUM) to chromosome 12q21.3-q22.

Authors:  S Chakravarti; R L Stallings; N SundarRaj; P K Cornuet; J R Hassell
Journal:  Genomics       Date:  1995-06-10       Impact factor: 5.736

4.  Extracellular matrix lumican deposited on the surface of neutrophils promotes migration by binding to beta2 integrin.

Authors:  Seakwoo Lee; Kyle Bowrin; Abdel Rahim Hamad; Shukti Chakravarti
Journal:  J Biol Chem       Date:  2009-06-15       Impact factor: 5.157

5.  Lumican suppresses cell proliferation and aids Fas-Fas ligand mediated apoptosis: implications in the cornea.

Authors:  Neeraj Vij; Luke Roberts; Sarah Joyce; Shukti Chakravarti
Journal:  Exp Eye Res       Date:  2004-05       Impact factor: 3.467

6.  Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells.

Authors:  Dragana Nikitovic; Aikaterini Berdiaki; Alexandros Zafiropoulos; Pavlos Katonis; Aristidis Tsatsakis; Nikos K Karamanos; George N Tzanakakis
Journal:  FEBS J       Date:  2007-12-17       Impact factor: 5.542

7.  Expression of lumican in human lungs.

Authors:  M Dolhnikoff; J Morin; P J Roughley; M S Ludwig
Journal:  Am J Respir Cell Mol Biol       Date:  1998-10       Impact factor: 6.914

8.  Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma.

Authors:  Yoko Matsuda; Tetsushi Yamamoto; Mitsuhiro Kudo; Kiyoko Kawahara; Masashi Kawamoto; Yuki Nakajima; Kiyoshi Koizumi; Nando Nakazawa; Toshiyuki Ishiwata; Zenya Naito
Journal:  Int J Oncol       Date:  2008-12       Impact factor: 5.650

9.  Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican.

Authors:  S Chakravarti; T Magnuson; J H Lass; K J Jepsen; C LaMantia; H Carroll
Journal:  J Cell Biol       Date:  1998-06-01       Impact factor: 10.539

10.  Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site.

Authors:  Jordi Monfort; Ginette Tardif; Pascal Reboul; François Mineau; Peter Roughley; Jean-Pierre Pelletier; Johanne Martel-Pelletier
Journal:  Arthritis Res Ther       Date:  2006-01-03       Impact factor: 5.156

View more
  50 in total

Review 1.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

2.  Tissue mechanics and fibrosis.

Authors:  Rebecca G Wells
Journal:  Biochim Biophys Acta       Date:  2013-02-20

Review 3.  Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Authors:  Morten A Karsdal; Tina Manon-Jensen; Federica Genovese; Jacob H Kristensen; Mette J Nielsen; Jannie Marie B Sand; Niels-Ulrik B Hansen; Anne-Christine Bay-Jensen; Cecilie L Bager; Aleksander Krag; Andy Blanchard; Henrik Krarup; Diana J Leeming; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-03-12       Impact factor: 4.052

4.  Versican: a novel modulator of hepatic fibrosis.

Authors:  Terence N Bukong; Sean B Maurice; Barinder Chahal; David F Schaeffer; Paul J Winwood
Journal:  Lab Invest       Date:  2016-01-11       Impact factor: 5.662

Review 5.  Proteoglycans in liver cancer.

Authors:  Kornélia Baghy; Péter Tátrai; Eszter Regős; Ilona Kovalszky
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 6.  Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology.

Authors:  Madalina V Nastase; Renato V Iozzo; Liliana Schaefer
Journal:  Biochim Biophys Acta       Date:  2014-02-05

Review 7.  Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Pharmaceut Med       Date:  2019-12

8.  GDE5 inhibition accumulates intracellular glycerophosphocholine and suppresses adipogenesis at a mitotic clonal expansion stage.

Authors:  Yuri Okazaki; Keishi Nakamura; Shuto Takeda; Ikumi Yoshizawa; Fumiyo Yoshida; Noriyasu Ohshima; Takashi Izumi; Janet D Klein; Thanutchaporn Kumrungsee; Jeff M Sands; Noriyuki Yanaka
Journal:  Am J Physiol Cell Physiol       Date:  2018-11-21       Impact factor: 4.249

9.  TNF-α-stimulated fibroblasts secrete lumican to promote fibrocyte differentiation.

Authors:  Darrell Pilling; Varsha Vakil; Nehemiah Cox; Richard H Gomer
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-08       Impact factor: 11.205

10.  Quantitative proteomic and phosphoproteomic profiling of ischemic myocardial stunning in swine.

Authors:  Xue Wang; Xiaomeng Shen; Brian R Weil; Rebeccah F Young; John M Canty; Jun Qu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-03-30       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.